Targeting the somatostatin receptor in pituitary and neuroendocrine tumors

Bibliography

• Oberg K. Management of neuroendocrine tumours. Ann Oncol 2004;15(Suppl 4):iv293-8
   Google Scholar
• Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol 2010;21(Suppl 7):vii72-80
   PubMedGoogle Scholar
• de Herder WW, van der Lely AJ, Lamberts SW. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 1996;72:403-8
   PubMedGoogle Scholar
• Greenman Y, Stern N. Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:625-38
   PubMedGoogle Scholar
• Feelders RA, de Herder WW, Neggers SJ, et al. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc) 2013;49:89-103
   PubMed Web of Science ®Google Scholar
• De Martino MC, Hofland LJ, Lamberts SW. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 2010;182:255-80
   Google Scholar
• Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012;24:282-93
   Google Scholar
• Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-82
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
   PubMed Web of Science ®Google Scholar
• Cordoba-Chacon J, Gahete MD, Duran-Prado M, et al. Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Ann NY Acad Sci 2011;1220:6-15
   Google Scholar
• Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002;296:1636-9
   PubMed Web of Science ®Google Scholar
• Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18:R233-51
   Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279:21374-82
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. Cell biology. A last GASP for GPCRs? Science 2002;297:529-31
   PubMed Web of Science ®Google Scholar
• Patel YC, Srikant CB. Somatostatin receptors. Trends Endocrinol Metab 1997;8:398-405
   PubMed Web of Science ®Google Scholar
• Olias G, Viollet C, Kusserow H, et al. Regulation and function of somatostatin receptors. J Neurochem 2004;89:1057-91
   PubMed Web of Science ®Google Scholar
• Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006;13:955-62
   PubMed Web of Science ®Google Scholar
• Unger N, Ueberberg B, Schulz S, et al. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues. Exp Clin Endocrinol Diabetes 2012;120:482-9
   PubMed Web of Science ®Google Scholar
• Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol 2008;286:58-62
   PubMed Web of Science ®Google Scholar
• Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502-11
   PubMed Web of Science ®Google Scholar
• Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol 2007;156(Suppl 1):S3-11
   Google Scholar
• Ramirez JL, Watt HL, Rocheville M, et al. Agonist-induced up-regulation of human somatostatin receptor type 1 is regulated by beta-arrestin-1 and requires an essential serine residue in the receptor C-tail. Biochim Biophys Acta 2005;1669:182-92
   Google Scholar
• Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009;94:654-61
   PubMed Web of Science ®Google Scholar
• Csaba Z, Peineau S, Dournaud P. Molecular mechanisms of somatostatin receptor trafficking. J Mol Endocrinol 2012;48:R1-12
   PubMed Web of Science ®Google Scholar
• Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1-23
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. Somatostatin receptors: tachyphylaxis. In: Lamberts SW, Ghigo E, editors. The epxanding role of octreotide II: advances in endocrinology and eye diseases. Bioscientifica Ltd; Bristol: 2002. p. 235-50
   Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246-54
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Malagon MM, Gracia-Navarro F, et al. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol Cell Endocrinol 2008;286:63-8
   PubMed Web of Science ®Google Scholar
• Colao A, Filippella M, Pivonello R, et al. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 2007;156(Suppl 1):S57-63
   Google Scholar
• Culler MD. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011;43:854-7
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 2009;94:2634-43
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 2010;95:2497-502
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Waaijers AM, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 2009;42:47-56
   PubMed Web of Science ®Google Scholar
• Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010;362:1846-8
   PubMed Web of Science ®Google Scholar
• de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab 2012;97:455-62
   PubMed Web of Science ®Google Scholar
• Ferone D, Gatto F, Arvigo M, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009;42:361-70
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Feelders RA, de Herder WW, et al. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol 2010;326:89-98
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2013;98:E66-71
   PubMed Web of Science ®Google Scholar
• Tateno T, Kato M, Tani Y, et al. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 2009;56:579-84
   PubMed Web of Science ®Google Scholar
• Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 2009;10:83-90
   PubMed Web of Science ®Google Scholar
• Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012;1826:255-71
   PubMed Web of Science ®Google Scholar
• Tsuta K, Wistuba II, Moran CA. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. Pathol Res Pract 2012;208:470-4
   Google Scholar
• Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5-21
   PubMed Web of Science ®Google Scholar
• Ghazi AA, Amirbaigloo A, Dezfooli AA, et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine 2013;43:293-302
   PubMed Web of Science ®Google Scholar
• Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Wada R, Yajima N, et al. Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas 2010;39:1147-54
   PubMed Web of Science ®Google Scholar
• de Jong M, Breeman WA, Kwekkeboom DJ, et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009;42:873-80
   PubMed Web of Science ®Google Scholar
• Pinchot SN, Holen K, Sippel RS, et al. Carcinoid tumors. Oncologist 2008;13:1255-69
   Google Scholar
• Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 1996;20:126-31
   PubMed Web of Science ®Google Scholar
• Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol 2009;5:276-83
   PubMed Web of Science ®Google Scholar
• Gustafsson BI, Hauso O, Drozdov I, et al. Carcinoid heart disease. Int J Cardiol 2008;129:318-24
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93
   PubMed Web of Science ®Google Scholar
• Jais P, Terris B, Ruszniewski P, et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 1997;27:639-44
   PubMedGoogle Scholar
• Culler MD, Oberg K, Arnold R, et al. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011;30(Suppl 1):9-17
   Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol 2013;40:120-33
   PubMed Web of Science ®Google Scholar
• Ruggeri RM, Ferrau F, Campenni A, et al. Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone- secreting adrenal phaeochromocytoma: review of the literature and report of a case. Eur J Histochem 2009;53:1-6
   Google Scholar
• Georgantzi K, Tsolakis AV, Stridsberg M, et al. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer 2011;56:584-9
   Google Scholar
• Saveanu A, Muresan M, De Micco C, et al. Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011;18:287-300
   Google Scholar
• Carrasquillo JA, Pandit-Taskar N, Chen CC. Radionuclide therapy of adrenal tumors. J Surg Oncol 2012;106:632-42
   Google Scholar
• Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242-4
   PubMed Web of Science ®Google Scholar
• van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2013;97(1):74-85
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78-88
   Google Scholar
• Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004;102:61-85
   PubMed Web of Science ®Google Scholar
• Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002;57:425-41
   Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012;212:49-60
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;95:2781-9
   PubMed Web of Science ®Google Scholar
• Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012;366:914-24
   PubMed Web of Science ®Google Scholar
• FDA. U.S. Food and Drug Administration. Available from: www.fda.gov [Cited 7 June 2013]
   Google Scholar
• EMA. The European Medicines Agency. Available from: http://www.ema.europa.eu/ema/ [Cited 7 June 2013]
   Google Scholar
• Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657-66
   PubMed Web of Science ®Google Scholar
• Pasquali D, Rossi V, Conzo G, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008;40:263-71
   PubMed Web of Science ®Google Scholar
• Afargan M, Janson ET, Gelerman G, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001;142:477-86
   PubMed Web of Science ®Google Scholar
• Shimon I, Rubinek T, Hadani M, et al. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest 2004;27:721-7
   PubMed Web of Science ®Google Scholar
• Plockinger U, Hoffmann U, Geese M, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 2012;166:223-34
   PubMed Web of Science ®Google Scholar
• Reubi JC, Eisenwiener KP, Rink H, et al. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;456:45-9
   PubMed Web of Science ®Google Scholar
• Liu Q, Cescato R, Dewi DA, et al. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 2005;68:90-101
   PubMed Web of Science ®Google Scholar
• Cescato R, Loesch KA, Waser B, et al. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010;24:240-9
   PubMed Web of Science ®Google Scholar
• Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol 2011;25:1040-54
   PubMed Web of Science ®Google Scholar
• Ferone D, Saveanu A, Culler MD, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007;156(Suppl 1):S23-8
   Google Scholar
• Cescato R, Waser B, Fani M, et al. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med 2011;52:1886-90
   PubMed Web of Science ®Google Scholar
• Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011;52:1412-17
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009;625:131-42
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
   PubMed Web of Science ®Google Scholar
• Torrisani J, Hanoun N, Laurell H, et al. Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology 2008;149:3137-47
   PubMed Web of Science ®Google Scholar
• Veenstra MJ, van Koetsveld PM, Farrell WE, et al. Upregulation of sst2 by the demethylating agent 5-aza-2-deoxycytidine augments uptake of radiolabeled somatostatin analogue in human sst2 expressing cell lines. 2012: The Endocrine Society's Meeting & Expo – ENDO; Houston, TX; 2012
   Google Scholar
• Liu Z, Marquez M, Nilsson S, et al. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep 2008;20:151-4
   Google Scholar
• Alexander VM, Roy M, Steffens KA, et al. Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med 2010;3:95-102
   PubMedGoogle Scholar
• Mohammed TA, Holen KD, Jaskula-Sztul R, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011;16:835-43
   PubMed Web of Science ®Google Scholar
• Larsson C. Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2013;97(1):19-25
   Google Scholar
• Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer 2013;20(3):R65-82
   PubMed Web of Science ®Google Scholar
• Acunzo J, Thirion S, Roche C, et al. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res 2008;68:10163-70
   Google Scholar
• Cuny T, Mohamed A, Graillon T, et al. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Mol Cell Endocrinol 2012;355:106-13
   PubMed Web of Science ®Google Scholar
• Leja J, Dzojic H, Gustafson E, et al. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 2007;13:2455-62
   PubMed Web of Science ®Google Scholar
• Leja J, Nilsson B, Yu D, et al. Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS ONE 2010;5:e8916
   PubMedGoogle Scholar
• Leja J, Yu D, Nilsson B, et al. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther 2011;18:1052-62
   Google Scholar
• Essand M. Virotherapy of neuroendocrine tumors. Neuroendocrinology 2013;97:26-34
   Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286:69-74
   PubMed Web of Science ®Google Scholar
• Scoazec JY. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology 2012;97(1):45-56
   Google Scholar
• Gazal S, Gelerman G, Ziv O, et al. Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J Med Chem 2002;45:1665-71
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Guillen S, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83:258-63
   PubMed Web of Science ®Google Scholar
• Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99:789-98
   PubMed Web of Science ®Google Scholar
• Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-41
   PubMed Web of Science ®Google Scholar
• Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003;88:5414-21
   PubMed Web of Science ®Google Scholar